Ligand agrees to acquire core assets, partnered programmes and ion channel technologies from Icagen

This article was originally published here

The acquired assets include Icagen’s partnered programs with Roche focused on neurological diseases, and with the Cystic Fibrosis Foundation (CFF) focused on cystic fibrosis. Ligand is also acquiring

The post Ligand agrees to acquire core assets, partnered programmes and ion channel technologies from Icagen appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply